TickerFacts.

Compare

UL Solutions Inc. vs NeoGenomics Inc vs 20/20 Biolabs, Inc. vs Hypha Labs, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearUL Solutions Inc.
ULS		NeoGenomics Inc
NEO		20/20 Biolabs, Inc.
AIDX		Hypha Labs, Inc.
FUNI
Year ended2025-12-312025-12-312025-12-312025-09-30
Revenue$3.05B$727.33M$2.05Mn/a
Revenue growth (YoY)+6.4%+10.1%+16.7%n/a
Gross margin49.5% (computed)43.2%29.6%n/a
Operating margin17.1%-15.9%-162.9%n/a
Net margin10.6%-14.9%-182.8%n/a
Net income$325.00M-$108.03M-$3.74M-$3.10M
EPS (Diluted)$1.60n/a-$0.76-$0.02
Operating cash flow$600.00M$5.23M-$1.92M-$380.0K
Free cash flow$403.00M-$21.78Mn/a-$412.9K
Cash & equivalents$295.00M$159.62M$1.03Mn/a
Total assets$2.92B$1.36B$4.14M$409.2K
Total liabilities$1.63B$523.27M$4.16M$2.51M
Shareholders' equity$1.29B$836.56M-$19.2K-$2.44M
Return on year-end equity25.1%-12.9%n/an/a
Shares outstanding201.03M128.15M5.44M147.12M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearUL Solutions Inc.NeoGenomics Inc20/20 Biolabs, Inc.Hypha Labs, Inc.
Latest$3.05B
Ended 2025-12-31		$727.33M
Ended 2025-12-31		$2.05M
Ended 2025-12-31		$2.70M
Ended 2022-09-30
1 year earlier$2.87B
Ended 2024-12-31		$660.57M
Ended 2024-12-31		$1.75M
Ended 2024-12-31		$2.50M
Ended 2021-09-30
2 years earlier$2.68B
Ended 2023-12-31		$591.64M
Ended 2023-12-31		n/a$2.57M
Ended 2020-09-30
3 years earlier$2.52B
Ended 2022-12-31		$509.73M
Ended 2022-12-31		n/a$2.55M
Ended 2019-09-30
4 years earliern/a$484.33M
Ended 2021-12-31		n/a$2.84M
Ended 2018-09-30